Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
9 hedge funds and large institutions have $380M invested in Sinovac Biotech, Ltd in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 21 closing their positions.
758% more capital invested
Capital invested by funds: $44.3M → $380M (+$336M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
70% less funds holding
Funds holding: 30 → 9 (-21)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 21
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.54M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.04M |
| 3 |
YMRC
Yorktown Management & Research Company
Forest,
Virginia
|
-$485K |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$259K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$179K |
SVA Hedge Fund Activity: Q4 2022 in Review
9 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2022, worth a combined $380M — up 758% from $44.3M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SVA and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 1 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.54M sold.
- 9 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2022, down from 30 in Q3 2022.
- Funds reported $380M of Sinovac Biotech, Ltd stock for Q4 2022, up 758% quarter-over-quarter.
- 0 funds opened new Sinovac Biotech, Ltd positions in Q4 2022 and 21 closed out, a net change of -21 holders.
- The largest Sinovac Biotech, Ltd seller in Q4 2022 was Renaissance Technologies, an estimated $1.54M sold.
Based on aggregated 13F filings for Q4 2022.